

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 23, 2021

**INMED PHARMACEUTICALS INC.**

(Exact Name of Company as Specified in Charter)

**British Columbia**  
(State or Other Jurisdiction  
of Incorporation)

**001-39685**  
(Commission File Number)

**98-1428279**  
(IRS Employer  
Identification No.)

**InMed Pharmaceuticals Inc.**  
Suite 310 - 815 W. Hastings Street,  
Vancouver, B.C.  
Canada

(Address of Principal Executive Offices)

**V6C 1B4**  
(Zip Code)

Company's telephone number, including area code: (604) 669-7207

Not applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value	INM	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

On November 23, 2021, InMed Pharmaceuticals Inc. announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on November 29 – December 1, 2021.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">News release, dated November 23, 2021</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INMED PHARMACEUTICALS INC.

Date: November 23, 2021

By: /s/ Bruce Colwill  
Bruce Colwill  
Chief Financial Officer



Suite 310-815 W. Hastings St.  
Vancouver, BC, Canada V6C 1B4  
Tel: +1.604.669.7207  
Email: [info@inmedpharma.com](mailto:info@inmedpharma.com)  
[www.inmedpharma.com](http://www.inmedpharma.com)

### **InMed Pharmaceuticals to Participate in Cowen's 4th Annual Cannabis Conference**

Vancouver, BC – November 23, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on November 29 – December 1, 2021.

#### **Cowen’s 4th Annual Cannabis Conference**

**Date: November 29 - December 1, 2021**

Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your Cowen institutional representative or visit the conference website at <https://www.cowen.com/conferences-and-events/4th-annual-cannabis-conference/>

Cowen’s 4th Annual Cannabis Conference is a three-day conference comprising of topical panel discussions with C-Suite presenters, hosted by Cowen Research and Washington Research Group analysts, and virtual one-on-one meetings.

**About InMed:** InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit [www.inmedpharma.com](http://www.inmedpharma.com).

#### **Investor Contact:**

Colin Clancy  
Senior Director, Investor Relations  
T: +1 604 416 0999  
E: [cclancy@inmedpharma.com](mailto:cclancy@inmedpharma.com)

#### **Edison Group:**

Joe Green/Laine Yonker  
T: +1.646.653.7030/+1.646.653.7035  
E: [jgreen@edisongroup.com](mailto:jgreen@edisongroup.com) / [lyonker@edisongroup.com](mailto:lyonker@edisongroup.com)

#### **Cautionary Note Regarding Forward-Looking Information:**

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: participating in Cowen’s 4th Annual Cannabis Conference; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; and developing a pipeline of cannabinoid-based pharmaceutical drug candidates. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.